読み込み中
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
前日終値
$7.54
+$0.03 · +0.40%
日中の時刻はETです。市場データは遅延する場合があります。
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
日中レンジ
現在 $7.54
52週レンジ
現在 $7.54
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
34
割高
センチメント
68
強気
リスク
58
やや高いリスク
モメンタム
48
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
日中レンジ
現在 $7.54
52週レンジ
現在 $7.54
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5182.3万 USD | 6372.3万 USD | 5844.3万 USD | 5149.4万 USD | 4352.2万 USD |
| 売上原価 | 657.4万 USD | 562.6万 USD | 528.1万 USD | 454万 USD | 440.6万 USD |
| 粗利益 | 4524.9万 USD | 5809.7万 USD | 5316.2万 USD | 4695.4万 USD | 3911.6万 USD |
| 研究開発 | 1.97億 USD | 1.28億 USD | 6105.5万 USD | 5346.2万 USD | 5008.3万 USD |
| 販売・一般管理 | 1.18億 USD | 1.02億 USD | 7448.9万 USD | 7214.6万 USD | 6707万 USD |
| 営業費用 | 3.15億 USD | 2.3億 USD | 1.36億 USD | 1.26億 USD | 1.17億 USD |
| 受取利息 | 1835.5万 USD | 2028.2万 USD | 398.3万 USD | 79.8万 USD | 3.3万 USD |
| 支払利息 | 1183.5万 USD | 1357.7万 USD | 1133.8万 USD | 702.2万 USD | 667.1万 USD |
| 減価償却費と償却費 | 432.3万 USD | 378.6万 USD | 298.3万 USD | 210.9万 USD | 242.1万 USD |
| 営業利益 | −2.7億 USD | −1.72億 USD | −8238.2万 USD | −7865.4万 USD | −7803.7万 USD |
| 純利益 | −2.66億 USD | −1.94億 USD | −8073.6万 USD | −7103.8万 USD | −655.3万 USD |
会社概要が更新されました 2026年10月10日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI6962.14万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM4247.59万0.05%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2138.52万0.02%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO1241.85万0.07%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO1235.83万0.09%139.72億 USD0.24%$356.78+0.94%
Invesco Pharmaceuticals ETFPJP1222.64万2.23%5.41億 USD0.58%$122.88+1.56%
Dimensional - US Small Cap ETFDFAS933.49万0.03%338.69億 USD0.31%$78.35+0.32%
Schwab U.S. Small-Cap ETFSCHA733.15万0.03%217.28億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOInvesco Pharmaceuticals ETFPJPDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
